
Novan NOVN
Quarterly report 2023-Q1
added 05-15-2023
Novan Cash Conversion Cycle 2011-2026 | NOVN
Annual Cash Conversion Cycle Novan
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -159 | 276 | - | 8.01 | -19.8 | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 276 | -159 | 26.4 |
Quarterly Cash Conversion Cycle Novan
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -396 | - | 38.8 | 106 | -721 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 106 | -721 | -243 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Verastem
VSTM
|
38.5 | $ 5.04 | -4.73 % | $ 349 M | ||
|
Voyager Therapeutics
VYGR
|
14.8 | $ 3.96 | -4.12 % | $ 232 M | ||
|
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | ||
|
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | ||
|
Albireo Pharma
ALBO
|
-1.55 K | - | -0.23 % | $ 916 M | ||
|
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | ||
|
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | ||
|
Arena Pharmaceuticals
ARNA
|
946 | - | -6.81 % | $ 3.04 B | ||
|
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M | ||
|
Acorda Therapeutics
ACOR
|
117 | - | -24.86 % | $ 820 K | ||
|
bluebird bio
BLUE
|
-54.4 | - | - | $ 546 M | ||
|
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - | ||
|
Avid Bioservices
CDMO
|
85.5 | - | - | $ 789 M | ||
|
Advaxis
ADXS
|
-143 K | - | -9.65 % | $ 45.9 M | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
72.3 | $ 12.41 | -11.1 % | $ 1.88 B | ||
|
Wave Life Sciences Ltd.
WVE
|
11.5 | $ 6.37 | 2.66 % | $ 1.07 B | ||
|
Xenetic Biosciences
XBIO
|
-1.84 K | $ 2.72 | -2.86 % | $ 4.63 M | ||
|
XBiotech
XBIT
|
-1.26 K | $ 2.27 | -1.73 % | $ 69.2 M | ||
|
Xenon Pharmaceuticals
XENE
|
72.6 | $ 54.48 | -1.89 % | $ 4.24 B | ||
|
Xeris Pharmaceuticals
XERS
|
535 | $ 5.4 | -3.05 % | $ 866 M | ||
|
X4 Pharmaceuticals
XFOR
|
-408 | $ 4.04 | -6.26 % | $ 171 M | ||
|
Xencor
XNCR
|
131 | $ 11.42 | -7.23 % | $ 848 M | ||
|
XOMA Corporation
XOMA
|
23.6 | $ 30.17 | -1.18 % | $ 364 M | ||
|
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B | ||
|
22nd Century Group
XXII
|
108 | $ 2.41 | -18.03 % | $ 444 K | ||
|
BioDelivery Sciences International
BDSI
|
340 | - | -4.8 % | $ 255 M | ||
|
Cara Therapeutics
CARA
|
52.4 | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
3.1 | - | - | $ 3.74 B | ||
|
Zai Lab Limited
ZLAB
|
-46.6 | $ 18.0 | 2.8 % | $ 19.7 B | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
-193 | $ 1.05 | -3.67 % | $ 21.5 M |